G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Address

Frontier 700
700 Park Offices Drive
Suite 200
RTP, NC 27709

Additional Details

Arrived in RTP:
2014
University Affiliation:
Duke University, UNC-Chapel Hill

Get In Touch

Phone:
(919) 213-9835
Fax:
(919) 741-5830
Twitter:
@G1Therapeutics
Mailing Address:
PO Box 110341
RTP, NC 27709
General Contact:
jmacdonald@g1therapeutics.com